期刊文献+

痛风汤配合放血疗法治疗痛风性关节炎临床疗效分析 被引量:12

Clinical efficacy of Gout Decoction combined with bloodletting therapy on gouty arthritis
在线阅读 下载PDF
导出
摘要 目的观察痛风汤配合放血疗法治疗痛风性关节炎的临床疗效。方法 40例符合纳入标准的患者随机分为2组,治疗组予痛风汤、秋水仙碱及针刺放血疗法,对照组仅予口服秋水仙碱。观察主要症状(红、肿、热、痛)改善情况、不良反应发生率以及综合疗效。结果治疗组总有效率达100.0%,显著高于对照组(68.4%)(P<0.05)。2组患者治疗后症状积分均较治疗前显著下降(P<0.01);且治疗后治疗组症状积分明显低于对照组(P<0.01)。2组患者治疗期间无不良反应发生。结论口服痛风汤配合放血疗法治疗痛风性关节炎可显著提高疗效,且安全性高,值得推广。 Objective To observed the clinical effect of Gout Decoction combined with bloodletting therapy on gouty arthritis. Methods Forty patients with gouty arthritis were divided into two groups. The treatment group received Gout Decoction, colchicin and bloodletting therapy, while the control group received colchicin alone. The improving condition of main symptoms (red, swollen, heat, pain), incidence of adverse reactions and comprehensive effect of the two groups were observed. Results The overall effectiveness rate in the treatment group (100.0 % ) was obvi- ously higher than that in the control group (68.4 % ) (P 〈 0.05). After treatment, the symptom scorings in the two groups decreased obviously (P〈 0.01 ), and the symptom seorings in the treatment group were obviously lower than that in the control group (P〈0.01). There was no adverse reaction in the two groups during therapy. Conclusion Gout Decoction combined with bloodletting therapy on gouty arthritis can obviously enhance the curative effect with high safety, and is worthy of popularization.
作者 王燕丽
出处 《实用临床医药杂志》 CAS 2012年第21期136-137,146,共3页 Journal of Clinical Medicine in Practice
关键词 痛风汤 放血疗法 痛风性关节炎 秋水仙碱 Gout Decoction bloodletting therapy gouty arthritis colchicin
  • 相关文献

参考文献10

二级参考文献96

共引文献72

同被引文献101

  • 1施财富.中药熏蒸治疗痛风性关节炎42例[J].中医杂志,2005,46(3):207-208. 被引量:12
  • 2王维宁.痛风病人的中西医结合护理[J].护理研究(上旬版),2006,20(2):299-300. 被引量:20
  • 3宋必卫 王洁 陈志武 等.氧自由基对疼痛的调控作用[J]..中国神经科学会第一届学术会议摘要汇编[C].上海:中国神经科学会,1995.12.
  • 4陆再英,钟南山,谢毅,胡品津.内科学第七版[M].北京:人民卫生出版社,2007:86-90.
  • 5潘天鹏 石津生.现代系统老年医学[M].北京:科学出版社,1997.491-518.
  • 6姚凤祥.现代风湿病学[M].北京:人民军医出版社,1997:381,373.
  • 7Tetlow L C, Woolley D E. Mast cells, cytokines , and metalloproteinases at the rheumatoid lesion : dual immunolocalisation studies[J]. Ann Rheum Dis, 1995, 54(11): 896.
  • 8Li YY, McTiernanCF, FeldmanAM. Interplay of matrix metalloproteinses , tissue inhibitors of metalloproteinases and their regulators in cardi2ac matrix remodeling[J]. Cardiovasc Res, 2000, 46(2): 2142224.
  • 9Okada Y, Nagase H, Harris ED Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components [J]. J Biol Chem, 1986, 261(30): 14245.
  • 10Yamanaka H, Matsuda Y. TanakaM, et al. Serum ma-trixmetalloproteinase 3 as a predictor of the degree of joint destruction during the sixmonths aftermeasurement in patientswith early rheumatoid arthritis [J]. Arthritis Rheum, 2000,43: 852.

引证文献12

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部